Global Biopharma Layoffs August 2026

Aura Biosciences

Aura Biosciences is reducing its workforce by approximately 20% as the company sharpens its focus on advancing its ocular oncology pipeline. With 113 employees on staff earlier this year, the restructuring could affect roughly 23 positions.

The biotech's primary focus remains the development of belzupacap sarotalocan (bel-sar), which is being evaluated for choroidal metastases, ocular surface cancers and early-stage choroidal melanoma. Aura recently completed enrollment in its Phase 3 CoMpass study and expects to report topline results from the trial's primary endpoint in the second half of 2027.

Alongside the workforce reduction, the company is scaling back investment in its non-muscle invasive bladder cancer program and implementing several leadership changes. Aura expects the restructuring to cost between $2.9 million and $3.2 million and believes the measures will extend its cash runway into the first half of 2029.

Schrödinger

Schrödinger has carried out a targeted workforce reduction as part of a strategic shift away from independently advancing clinical-stage drug programs. The company did not disclose how many employees were affected but said the cuts were concentrated within teams supporting internal clinical development activities.

The restructuring reflects Schrödinger's decision to place greater emphasis on partnership-based development and commercialization opportunities while continuing to invest in its computational drug discovery platform and core technology capabilities.

Known for its physics-based software used in molecular modeling and drug design, Schrödinger maintains a pipeline focused largely on oncology, inflammation and immunology while collaborating with major pharmaceutical companies on drug discovery initiatives. The company previously reduced its workforce in 2025, eliminating 60 positions to lower operating expenses.

aTyr Pharma

aTyr Pharma is cutting approximately 60% of its workforce as it concentrates resources on advancing its lead candidate, efzofitimod. Following the restructuring, the San Diego-based biotech expects to retain about 20 employees.

Efzofitimod is being developed for interstitial lung diseases, including pulmonary sarcoidosis and systemic sclerosis-associated ILD. The company is currently awaiting FDA feedback on the design of a planned Phase 3 study in pulmonary sarcoidosis while continuing a Phase 2 trial in systemic sclerosis-related ILD.

The reorganization also includes leadership changes, with Chief Financial Officer Jill Broadfoot and General Counsel Nancy Denyes set to transition out of their executive roles and become consultants. aTyr estimates the restructuring will generate annual operating expense savings of roughly $13 million and extend its cash runway into late 2028.

Arpeggio Biosciences

Arpeggio Biosciences has decided to wind down operations after encountering development challenges with its lead oncology program. The Colorado-based startup employed roughly a dozen people and is now joining a growing list of early-stage biotech companies forced to shut down amid scientific and funding pressures.

The company's most advanced asset, an NRF2 degrader for non-small cell lung cancer, ultimately failed to demonstrate a sufficiently differentiated efficacy profile from an off-target safety concern. According to CEO Joey Azofeifa, this setback made it difficult to justify continued investment in the program.

Despite its closure, Arpeggio highlighted several scientific achievements during its brief history, including the generation of millions of experimental data points, extensive transcriptomic analysis and the creation of more than 2,000 proprietary small molecules across multiple discovery programs.

Ensoma

Ensoma is reducing its workforce for the second time in less than a year as the Boston-based biotech concentrates its resources on its lead program and seeks additional financing. The company confirmed the restructuring on Aug. 7 but did not disclose how many employees were affected.

Under the reorganization, Ensoma is prioritizing development of EN-374 for X-linked chronic granulomatous disease (X-CGD) and clinical validation of its platform in other therapeutic areas. Investment and research on several earlier-stage programs have been put on hold while the company works to secure additional funding.

The latest cuts follow a much larger reduction in November, when Ensoma eliminated half of its workforce. The company subsequently said that 37 employees remained. EN-374, an in vivo gene insertion therapy targeting hematopoietic stem cells, entered the clinic in December after the first patient was dosed in a Phase 1/2 trial for X-CGD, a rare genetic disorder that impairs the immune system's ability to fight infections.

The programs now on pause were still in the research stage and included candidates targeting sickle cell disease, solid tumor immuno-oncology and hematologic oncology.

Emergent BioSolutions

Emergent BioSolutions is restructuring its operations to better match current business needs, a move that will eliminate 93 jobs and 21 currently vacant positions. The changes were announced alongside the company's second-quarter financial results.

The workforce reduction represents a relatively small portion of Emergent's approximately 900 employees. The company did not identify all of the locations affected, but said the restructuring will include the closure of wet laboratories at its headquarters in Gaithersburg, Maryland.

The organizational changes will also eliminate the chief medical officer and head of research and development position, resulting in Simon Lowry's departure from Emergent on Aug. 19. At the same time, the company is establishing a new growth organization that will bring together R&D, business development and strategy. Stephanie Duatschek, previously the company's senior vice president and chief global strategy and franchise development officer, will lead the new group as executive vice president and chief growth officer.

Emergent expects the restructuring to result in approximately $10 million to $11.5 million in related costs. The company reported $139.7 million in cash and cash equivalents as of June 30.

Aurora Therapeutics

Aurora Therapeutics is scaling back its early development strategy, discontinuing its lead gene-editing program for phenylketonuria (PKU) and laying off several employees. The decision comes as the young biotech reassesses its position in an increasingly competitive PKU research landscape.

Aurora launched in January with $16 million in seed funding from Menlo Ventures and initially focused on developing an N-of-1 gene-editing approach for PKU, a rare inherited disorder in which the body cannot properly process the amino acid phenylalanine.

The company has now decided to deprioritize the PKU program after other biotech companies began pursuing similar approaches. As a result, several members of Aurora's team have been let go, although the company has not disclosed the exact number of affected employees.

Pfizer

Pfizer is expanding its ongoing cost-reduction initiative by an additional $2.5 billion, with a significant portion of the savings expected to come from technology-driven efficiencies and operational simplification across its commercial, research and development, and manufacturing organizations.

As part of its "Realigning Our Cost Base Program," the company expects to generate approximately $1 billion in savings between 2027 and 2029. The initiative was outlined in Pfizer's second-quarter earnings report released on Aug. 4.

The restructuring will require substantial upfront investment, however. Pfizer estimates it will incur roughly $2 billion in one-time expenses related to digital transformation efforts, implementation costs and employee severance. The company has not disclosed whether specific positions will be eliminated or provided details regarding the scope of any workforce impact.

Lisata Therapeutics

Lisata Therapeutics has reduced approximately 72% of its full-time workforce following the collapse of its planned merger with Kuva Labs. Based on the company's reported headcount of 21 employees at the end of 2025, the restructuring is estimated to affect around 15 positions.

The workforce reduction is intended to lower operating expenses and preserve cash while the company evaluates strategic alternatives. Lisata, which focuses on therapies for advanced solid tumors and other serious diseases, confirmed that senior leadership was also impacted, including Executive Vice President of Research and Development and Chief Medical Officer Kristen Buck.

At the same time, Lisata has filed a lawsuit against Kuva Labs, alleging that the company breached the parties' merger agreement. Lisata is seeking financial damages on behalf of its shareholders, as well as a $2 million termination fee that it claims is owed under the terms of the deal.

Supernus Pharmaceuticals & Indivior Pharmaceuticals

The planned merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals is expected to create some workforce overlap, potentially resulting in "natural redundancies" among general and administrative functions, according to Supernus CEO Jack Khattar during an Aug. 3 investor call.

The companies did not provide specific details on the number of positions that could be affected, and no additional information was included in the merger announcement or related SEC filings. Based on their latest annual reports, Supernus employed 778 people as of Dec. 31, while Indivior had a workforce of 838 employees.

The all-stock merger of equals will combine the two companies into a central nervous system–focused pharmaceutical business. The combined company is expected to generate approximately $2.2 billion in annual revenue, with projected operating earnings of around $888 million.